Anti CD19 car-t cell therapy! Bristol Myers Squibb LISO cel in the treatment of relapsed / refractory large B cell NHL total remission rate of 100%!

December 11, 2019 / BIOON / -- the 61st annual meeting of the American Society of Hematology (ash2019) was recently held in Orlando, Florida, USA At this meeting, BMS released the preliminary data of phase II pilot study of anti-CD19 car-t cell therapy lisocabatagene maraleucel (jcar017) in the treatment of relapsed or refractory large B-cell non-Hodgkin's lymphoma (R / R B-NHL) In this study, patients received only one previous immunochemotherapy regimen and were considered incompatible with hematopoietic stem cell transplantation (HSCT) due to age, comorbidity or performance status (PS) At the time of data cut-off, 19 patients were treated with leukemia isolation and 13 patients were treated with LISO cel after lymphocyte depletion In terms of safety, 8 of the 13 patients (61.5%) experienced at least one level 3 adverse event (teae), mainly hemocytopenia 4 cases (31%) had grade 3 or more hemocytopenia on the 29th day Three patients (0.23%) had CRS of grade 1-2 No level 5 teae occurred None of the six outpatients were admitted within the first 29 days after LISO cel infusion In terms of efficacy, all 12 patients (100%) who met the remission assessment got remission after treatment, i.e the overall remission rate (ORR) was 100%, and 6 patients (50%) got complete remission (CR) Among the 12 patients, 7 (58%) maintained remission within 3 months after LISO cel infusion These preliminary results show that LISO cel as a second-line therapy has good efficacy and safety in patients with aggressive, relapsed or refractory large B-cell non-Hodgkin's lymphoma who are not eligible for hematopoietic stem cell transplantation Stanley Frankel, senior vice president of cell therapy development at Bristol Myers Squibb, said: "as we continue to evaluate LISO cel in important new disease environments and areas that do not meet medical needs, we are encouraged by early results from a number of studies Data from the pilot study confirm the therapeutic potential of LISO cel in patients with second-line relapse or refractory large B cell NHL who cannot receive hematopoietic stem cell transplantation " LISO cel was developed by Juno, and Juno was newly acquired on the basis of US $9 billion in January 2018 It is a car-t cell therapy targeting at CD19 antigen and taking 4-1BB as co stimulatory region, in which CD4 + and CD8 + car-t cells have an accurate 1:1 ratio LISO cel represents the current best in class CD19 targeted car-t therapy, which has previously been awarded a breakthrough drug qualification by the US FDA In early January, Bristol Myers Squibb announced a $74 billion acquisition of new base After a series of twists and turns, the huge acquisition was successfully completed on November 21, 2019 LISO cel is expected to become the third car-t cell therapy on the market, which is in line with Novartis, the two car-t cell therapies on the market Kymriah and Gilead yescarta target the same target, but the patients who received LISO cel treatment separated CD4 cells and CD8 cells in advance before carrying out chimeric antigen receptor (car) transduction, and then the cells after the respective transduction were retransmitted to the patients in a specific ratio of 1:1, which is better than the safety data of other car-t therapies, such as the overview of cytokine storm The rate is lower Original source: Bristol Myers Squibb announcements studies evaluating list cel in multiple additional patient populations, site of care and disease areas presented at American Society of Geography (ash) annual meeting